Compare Illumina, Inc. (ILMN) vs Toronto-Dominion Bank (TD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Illumina, Inc. vs Toronto-Dominion Bank — how do they compare? Illumina, Inc. trades at $189.79 (market cap $27.94B), while Toronto-Dominion Bank trades at $120.42 (market cap $197.03B). The key difference: Toronto-Dominion Bank is far larger — about 7.1× Illumina, Inc.'s market cap, and Toronto-Dominion Bank pays a 2.62% dividend while Illumina, Inc. pays none. Which is the better fit depends on your goals.
| ILMN | TD | |
|---|---|---|
Market Cap | $27.94B | $197.03B |
Sector | Health | Financials |
52-Week High | $194.33 | $124.80 |
52-Week Low | $91.00 | $72.55 |
Enterprise Value | $29.33B | — |
Dividend Yield | — | 2.62% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $185.36, down 0.69% on the day, with a bullish technical signal from moving averages. The stock shows strong profitability with a 19.42% net income margin and has beaten EPS estimates for three consecutive quarters. Recent news highlights expansion of the Billion Cell Atlas program and upcoming Q2 2026 earnings on July 30.
Outlook remains positive with 51% analyst buy ratings, though the current price exceeds the $178 consensus target. Key risks include competitive pressure from Roche's new sequencer and China market weakness. Earnings growth and cost control initiatives support upside potential, but valuation multiples suggest limited near-term appreciation.
TD stock trades at $120.56, down 2.46% on the day, with strong technical momentum indicated by bullish moving averages. The company has consistently beaten earnings expectations in recent quarters, with Q1 2026 EPS of $1.74 exceeding the $1.63 estimate. Revenue growth remains steady, increasing from $56.3B in 2024 to $61.3B in 2025, while net income margin improved significantly to 33.51%.
Analyst consensus is bullish with a $153 price target representing 27% upside potential. Key risks include volatile cash flow patterns and high debt levels, while opportunities lie in continued earnings outperformance and dividend stability. The stock presents a compelling value proposition for investors seeking banking sector exposure with growth potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →About Toronto-Dominion Bank
Toronto-Dominion is one of Canada's two largest banks and operates three business segments: Canadian retail banking, U.S. retail banking, and wholesale banking. The bank's U.S. operations span from Maine to Florida, with a strong presence in the Northeast. It also has a 13% ownership stake in Charles Schwab.
Read more on TD →
